Peptide multimer products and methods
AssigneeThe Regents of the University of Michigan
InventorsThomas D. Wang, Shuo Feng
Life of this patent
Estimating the term…
Abstract
The disclosure relates to multimers of Glypican-3 (GPC3)-, CD44-, and Epithelial cell adhesion molecule (EpCAM)-specific peptides and the use thereof to detect and treat epithelial cell-derived cancers such as hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), breast cancer, colon cancer, gastric cancer, ovarian cancer, cervical cancer, and basal cell carcinoma of the skin. The disclosure also relates to methods to monitor the therapeutic response of treated patients using the peptide multimers.
Claims29
A peptide multimer comprising a GPC3-specific peptide, a CD44-specific peptide and an EpCAM-specific peptide,
- wherein the GPC3-specific peptide comprises the amino acids ALLANHEELFQT (SEQ ID NO:
- 1), ALLANHEELF (SEQ ID NO:
- 2), GLHTSATNLYLH (SEQ ID NO:
- 3), SGVYKVAYDWQH (SEQ ID NO:
- 4), or VGVESCASRCNN (SEQ ID NO:
- 5),
- wherein the CD44-specific peptide comprises the amino acids WKGWSYLWTQQA (SEQ ID NO:
- 6), and
- wherein the EpCAM-specific peptide comprises the amino acids HPDMFTRTHSHN (SEQ ID NO:
- 7), HGLHSMHNKLQD (SEQ ID NO:
- 8), GKPAVHYIHLRH (SEQ ID NO:
- 9), or HPFLHWNYGQRT (SEQ ID NO:
- 10).
The peptide multimer of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 comprising at least one therapeutic moiety attached to the peptide.
Dependencies are inferred from the claim text.